MedPath

Black Garlic Nutraceuticals and Blood Pressure Control

Not Applicable
Conditions
Hypertension
Interventions
Dietary Supplement: ABG+ Black Garlin
Dietary Supplement: Crystalline Cellulose
Registration Number
NCT04915053
Lead Sponsor
Universitat de Lleida
Brief Summary

Black garlic contains a series of allyl-sulfur compounds with the ability to modulate nitric oxide synthetase, angiotensin-converting enzyme system, and endothelial activation, which together could help better control blood pressure. The main objective of this study is to evaluate the effect on blood pressure and endothelial health of a daily intake of a black garlic supplement named ABG (registered mark), which has a higher concentration of black garlic bioactive compounds, in people with moderate hypertension.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Clinical hypertension, medically treated with no more than 2 drugs
Exclusion Criteria
  • Body mass index above 35 kg/m2
  • Fasting blood cholesterol levels below 115 mg/dL
  • Fasting blood glucose levels above 126 mg/dL
  • Taking anyone of the Angiotensin-converting enzyme inhibitors
  • Anemia (hemoglobin below 13 g/dL in men and below 12 g/dL in women)
  • Vitamin or nutraceutical intake in the last 30 days before the study enrollment
  • Chronic gastrointestinal diseases
  • Pregnancy and breastfeeding
  • Garlic allergy
  • Participation in another study 30 days before the study enrollment

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ABG Black Garlic ExtractABG+ Black GarlinDaily intake of a 550 mg tablet, containing 250 mg of Black Garlic Extract and 300 mg of excipients.
PlaceboCrystalline CelluloseDaily intake of a 550 mg tablet, containing 250 mg of microcrystalline cellulose and 300 mg of excipients
Primary Outcome Measures
NameTimeMethod
Change in Blood PressureBaseline and 12 weeks

Indirect measure of blood pressure by a trained physician

Secondary Outcome Measures
NameTimeMethod
Change in Blood nitric oxide contentBaseline and 12 weeks

Nitric oxide determined by nitrate and nitrite content in blood

Change in Angiotensin-converting enzyme activityBaseline and 12 weeks

Activity measured by a substrate-enzyme activity kit

Change in Endothelial functionBaseline and 12 weeks

Endothelial blood flow capacity

Change in Blood lipid profileBaseline and 12 weeks

Analysis of lipid profile (Total-cholesterol, LDL-cholesterol, Triacylglycerides, HDL-Cholesterol)

Change in Blood cytokine profileBaseline and 12 weeks

Analysis of cytokine profile (TNFa, IL-1b, IL-18, IL-6, IL-8, IL-17, IL-23, TGFb) in blood by immunoassays (Multiplexed)

Change in Blood antioxidant capacityBaseline and 12 weeks

Reduction capacity of blood determined by a biochemistry assay

Trial Locations

Locations (1)

Hospital Arnau de Vilanova

🇪🇸

Lleida, Spain

© Copyright 2025. All Rights Reserved by MedPath